Sameer Kejriwal

Sameer Kejriwal

Auto-generated profile, based on publicly available information

Sameer Kejriwal

John A Burns School of Medicine, Honolulu, HI, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 January 2020 in Journal of Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
KPKunal S. Patel
Kunal S. Patel
SKSameer Kejriwal
Sameer Kejriwal
MSMichel M. Sun
Michel M. Sun
STSamasuk Thammachantha
Samasuk Thammachantha
CDCourtney Duong
Courtney Duong
IYIsaac Yang
Isaac Yang

1 January 2020 in Neuro-Oncology Advances
Verified
Journal Article
Open access
PDF file
KPKunal S Patel
Kunal S Patel
SKSameer Kejriwal
Sameer Kejriwal
STSamasuk Thammachantha
Samasuk Thammachantha
CDCourtney Duong
Courtney Duong
AMAdrian Murillo
Adrian Murillo
MWMadhuri Wadehra
Madhuri Wadehra
Anti-angiogenic therapy with bevacizumab has failed to provide substantial gains in overall survival. Epithelial membrane protein 2 (EMP2) is a cell surface protein that has been previously shown to be expressed in glioblastoma, correlate with poor survival, and regulate neoangiogenesis in cell lines. Thus, the relationship of bevacizumab and EMP2 was investigated. Tumor samples were obtained from 12 patients with newly diagnosed glioblastoma at two time points: 1) during the initial surgery and 2) during a subsequent surgery following disease recurrence post bevacizumab treatment. Clinical characteristics and survival data from these patients were collected, and tumor samples were stained for EMP2 expression. The IVY glioblastoma atlas project database was used to evaluate EMP2 expression levels in 270 samples by differing histological areas of tumor. Patients with high EMP2 staining at initial diagnosis had decreased progression free and overall survival after bevacizumab [median progression free survival 4.6 months vs. 5.9 months; Log-Rank P = 0.076 & overall survival 7.7 months vs. 14.4 months; Log-Rank P = 0.011]. There was increased EMP2 staining in samples obtained after bevacizumab treatment in both unpaired [Mean H-score 2.31 vs 1.76; P=0.006] and paired analyses [Mean difference 0.571; P=0.019]. This expression increase correlated with length of bevacizumab therapy [R2=0.449; Pearson P=0.024]. Bevacizumab treatment increased EMP2 protein expression. This increase in EMP2 correlated with reduced mean survival time post bevacizumab therapy. We hypothesize a role of EMP2 in clinical bevacizumab resistance and as a potential anti-angiogenic therapeutic target in glioblastoma.

15 December 2023 in Interventional Pain Medicine
Verified
Journal Article
Open access
SKSameer Kejriwal
Sameer Kejriwal
EWEdward Weldon
Edward Weldon
DCDavis Carter
Davis Carter
KAKeinan Agonias
Keinan Agonias
JRJacob Razzouk
Jacob Razzouk
WCWayne Cheng
Wayne Cheng
Study design: Retrospective cohort study. Introduction: Malpractice claims analysis is performed by several specialties to improve quality of patient care and to identify areas where physicians can improve their practice to mitigate the incidence of committing malpractice. The Food and Drug Administration has flagged over 80,000 injuries caused by spinal cord stimulator (SCS), making them the 3rd most flagged medical device. This study analyzed malpractice claims due to SCS by querying two legal databases widely used in medicolegal research. Methods: Westlaw Edge and VerdictSearch were queried for malpractice cases filed between the years 2000 and 2022 using the keywords “spinal cord stimulator.” Case inclusion criteria was defined as a plaintiff's basis of litigation resting on a claim of medical malpractice due to SCS. Additional data collected included date of case hearing, plaintiff sex and age, defendant specialty, verdict ruling, location of the filed claim, payment or settlement amount, and sustained injuries. Result: Of the 1773 reviewed cases, 45 cases were included and categorized as battery or implantable pulse generator malfunction (35.56 %), lead complications (28.89 %), surgical complications (20.00 %), and miscellaneous (15.56 %). Four (8.89 %) cases resulted in settlement, 11 (24.44 %) in a plaintiff verdict, and 30 (68.00 %) resulted in a defendant verdict. Claims filed due to infection related to SCS were more likely to result in a defendant verdict ( p = .047), whereas claims filed due to neurological deficit were more likely to result in a plaintiff verdict (p = .020). The average settlement amount for the 4 cases is $1,975,309.61. Conclusion: Our findings suggest obtaining adequate neuroimaging preoperatively with MRIs, disclosing neurological risks specifically paralysis on informed consent, and evaluating radiography intraoperative and postoperatively with anterior-posterior (AP) and lateral x-ray films to ensure proper SCS placement are practices that may mitigate malpractice due to SCS. Battery defects and lead complications were the most common grounds for SCS-related malpractice claims.